Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT00720941

Public ClinicalTrials.gov record NCT00720941. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study VEG108844, A Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received prior systemic therapy for advanced or metastatic RCC.

Study identification

NCT ID
NCT00720941
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
1,110 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 14, 2008 (Actual)
Primary completion
May 21, 2012 (Actual)
Completion
Mar 24, 2021 (Actual)
Last update posted
Mar 30, 2025

2008 – 2021

United States locations

U.S. sites
96
U.S. states
34
U.S. cities
85
Facility City State ZIP Site status
Novartis Investigative Site Huntsville Alabama 35805 —
Novartis Investigative Site Tucson Arizona 85710 —
Novartis Investigative Site Little Rock Arkansas 72205 —
Novartis Investigative Site Beverly Hills California 90211 —
Novartis Investigative Site Escondido California 92025 —
Novartis Investigative Site Fresno California 93720 —
Novartis Investigative Site Greenbrae California 94904-2007 —
Novartis Investigative Site Hayward California 94545 —
Novartis Investigative Site La Jolla California 92037 —
Novartis Investigative Site Los Angeles California 90095 —
Novartis Investigative Site Montebello California 90640 —
Novartis Investigative Site Oakland California 94611 —
Novartis Investigative Site Orange California 92868 —
Novartis Investigative Site Roseville California 95661 —
Novartis Investigative Site Sacramento California 95817 —
Novartis Investigative Site Sacramento California 95825 —
Novartis Investigative Site San Bernardino California 92404 —
Novartis Investigative Site San Francisco California 94115 —
Novartis Investigative Site San Jose California 95119-1110 —
Novartis Investigative Site Santa Clara California 95051 —
Novartis Investigative Site South San Francisco California 94080 —
Novartis Investigative Site Vallejo California 94589 —
Novartis Investigative Site Walnut Creek California 94596 —
Novartis Investigative Site Denver Colorado 80218 —
Novartis Investigative Site Southington Connecticut 06489 —
Novartis Investigative Site Trumbull Connecticut 06611 —
Novartis Investigative Site Washington D.C. District of Columbia 20007 —
Novartis Investigative Site Fort Myers Florida 33916 —
Novartis Investigative Site Miami Florida 33136 —
Novartis Investigative Site Orlando Florida 32806 —
Novartis Investigative Site Atlanta Georgia 30318 —
Novartis Investigative Site Chicago Illinois 60612 —
Novartis Investigative Site Elk Grove Village Illinois 60007 —
Novartis Investigative Site Maywood Illinois 60153 —
Novartis Investigative Site Peoria Illinois 61615-7822 —
Novartis Investigative Site Carmel Indiana 46032 —
Novartis Investigative Site Indianapolis Indiana 46202 —
Novartis Investigative Site Indianapolis Indiana 46237 —
Novartis Investigative Site Cedar Rapids Iowa 52403 —
Novartis Investigative Site Louisville Kentucky 40202 —
Novartis Investigative Site Paducah Kentucky 42003 —
Novartis Investigative Site Annapolis Maryland 21401 —
Novartis Investigative Site Boston Massachusetts 02114 —
Novartis Investigative Site Boston Massachusetts 02115 —
Novartis Investigative Site Boston Massachusetts 02215 —
Novartis Investigative Site Worcester Massachusetts 01608 —
Novartis Investigative Site Detroit Michigan 48201 —
Novartis Investigative Site Duluth Minnesota 55805 —
Novartis Investigative Site Minneapolis Minnesota 55455 —
Novartis Investigative Site Tupelo Mississippi 38801 —
Novartis Investigative Site Kansas City Missouri 64118 —
Novartis Investigative Site Kansas City Missouri 64131 —
Novartis Investigative Site Lincoln Nebraska 68510 —
Novartis Investigative Site Las Vegas Nevada 89135 —
Novartis Investigative Site Las Vegas Nevada 89169 —
Novartis Investigative Site Lebanon New Hampshire 03756 —
Novartis Investigative Site Hackensack New Jersey 07601 —
Novartis Investigative Site Buffalo New York 14215 —
Novartis Investigative Site New York New York 10032 —
Novartis Investigative Site New York New York 10065 —
Novartis Investigative Site Hickory North Carolina 28602 —
Novartis Investigative Site Raleigh North Carolina 27607 —
Novartis Investigative Site Cincinnati Ohio 45242 —
Novartis Investigative Site Cleveland Ohio 44106 —
Novartis Investigative Site Columbus Ohio 43210 —
Novartis Investigative Site Columbus Ohio 43219 —
Novartis Investigative Site Dayton Ohio 45429 —
Novartis Investigative Site Oklahoma City Oklahoma 73120 —
Novartis Investigative Site Tulsa Oklahoma 74136 —
Novartis Investigative Site Eugene Oregon 97401 —
Novartis Investigative Site Portland Oregon 97213 —
Novartis Investigative Site Philadelphia Pennsylvania 19102 —
Novartis Investigative Site Philadelphia Pennsylvania 19111 —
Novartis Investigative Site Charleston South Carolina 29403 —
Novartis Investigative Site Charleston South Carolina 29425 —
Novartis Investigative Site Greenville South Carolina 29605 —
Novartis Investigative Site Mt. Pleasant South Carolina 29464 —
Novartis Investigative Site Chattanooga Tennessee 37404 —
Novartis Investigative Site Nashville Tennessee 37203 —
Novartis Investigative Site Arlington Texas 76012 —
Novartis Investigative Site Bedford Texas 76022 —
Novartis Investigative Site Corpus Christi Texas 78463-3069 —
Novartis Investigative Site Dallas Texas 75246 —
Novartis Investigative Site Fort Worth Texas 76104 —
Novartis Investigative Site Lubbock Texas 79410 —
Novartis Investigative Site Round Rock Texas 78681 —
Novartis Investigative Site San Antonio Texas 78229 —
Novartis Investigative Site Tyler Texas 75702 —
Novartis Investigative Site Webster Texas 77598-4420 —
Novartis Investigative Site Wichita Falls Texas 76310 —
Novartis Investigative Site Charlottesville Virginia 22903 —
Novartis Investigative Site Hampton Virginia 23666 —
Novartis Investigative Site Richmond Virginia 23230 —
Novartis Investigative Site Salem Virginia 24153 —
Novartis Investigative Site Seattle Washington 98101 —
Novartis Investigative Site Seattle Washington 98109 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 131 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00720941, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 30, 2025 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00720941 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →